Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. - Wikidata - wikimedia - TriplyDB

Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.

Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.

http://www.wikidata.org/entity/Q37838346

about

Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment The specialist physician's approach to rheumatoid arthritis in South Africa Validation of the rheumatoid arthritis diagnosis in the Swedish National Patient Register: a cohort study from Stockholm County.Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor.How to manage IBD in patients with infections or malignancies?The management of immunosuppression in patients with inflammatory bowel disease and cancer.Management of inflammatory bowel disease in the elderly: do biologicals offer a better alternative?Safety profile of biological therapies for treating rheumatoid arthritis.The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.The safety of monoclonal antibodies in asthma.Cancer immunotherapy in patients with preexisting autoimmune disorders.Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis.Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies.[Lung cancer and rheumatoid arthritis. An interdisciplinary challenge].[Safety of immunosuppressants].Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.Assessment and monitoring of biologic drug adverse events in patients with psoriasis.Looking beyond incidence in the relationship between anti-tumor necrosis factor therapy and malignancy

P2860

Q26745456-E964E025-D37C-4D7E-9ADD-43863F50B80F Q26765122-3CE87145-D110-48C0-8438-CB351C3DBB92 Q34996377-EAD4FF30-35C3-4DD1-80F8-D9E28BBCDED2 Q35605468-8E50DED6-DEF4-4021-9ABA-2D0AD96E6910 Q36361083-A51316DD-3D95-4506-9985-D8CDA2CD3599 Q37656273-93AFDEB5-E9EE-45D5-9778-49E4E64E181D Q38026407-19E1CA7F-078A-49F7-82A9-69BA0A9D6FC0 Q38125570-B33B1E9B-519A-479B-967B-1D1468FFD470 Q38141975-ECBF69E5-089B-4837-A9C3-40D9C40526DF Q38665700-7B648E98-81EF-4504-8096-DF294862D483 Q38755133-7C6ACD24-796A-4B85-99BC-42E6F0AF3316 Q38842153-285C710E-54A4-45FC-A311-5D5696148D22 Q38978399-84ABED6D-DE44-4784-B480-DD588F8BD765 Q39085984-958A9EE1-F4E6-4F7E-B8AB-42B5D9F39978 Q39309064-CDF713C8-43B2-4FB8-9972-529CF6E5243C Q39454180-3446F9CA-BCC0-499A-8466-BC6B7344114F Q40934508-85F65F4E-7FAB-43D7-8DAE-93C1E90AEEE6 Q41929021-D6B12A98-1735-4192-B636-F7BAC5CDE1AB Q42735059-7388E619-4214-4837-87E3-ED20889F572C Q55153984-910F2F41-9034-4C4D-A971-43C7687EE1D6 Q56969682-863DC7CD-65B6-4266-9533-C1ABA8CA6F98

P2860

Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.

http://www.wikidata.org/entity/Q37838346

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Does cancer that occurs during ...... treated with biologic agents.

@en

Does cancer that occurs during ...... treated with biologic agents.

@nl

type

label

Does cancer that occurs during ...... treated with biologic agents.

@en

Does cancer that occurs during ...... treated with biologic agents.

@nl

prefLabel

Does cancer that occurs during ...... treated with biologic agents.

@en

Does cancer that occurs during ...... treated with biologic agents.

@nl

P1433

Q37838346-81217305-064F-4E6A-A00D-800E6F8461AB

P1476

Q37838346-21CC7D9D-C297-4F4B-AAB9-585EF6842DF6

P2093

Q37838346-38840EE1-BAFC-477D-85C4-A54D52CC28AC

Q37838346-677589DB-8C47-401C-B8D4-41EAFB621F11

Q37838346-A9118774-6BE5-4362-885A-9CC7D409B222

P2860

Q37838346-0BE9E4DA-C4E4-4DC8-B08A-246030522F1D

Q37838346-114875E2-110D-4F9B-B7A9-4CDA273F4B98

Q37838346-13BF3504-007B-4F76-9012-3E5D6E5BC315

Q37838346-1480572D-2429-4196-B17B-521BDF2A5B45

Q37838346-2074183B-E402-425F-BF09-C488679863B2

Q37838346-31C12F0C-548B-4D58-9A47-059C5042BF05

Q37838346-3A0778BE-987D-47A6-B5F5-0391400A0E26

Q37838346-4DF9FC88-E866-4279-B926-0B60DA58EC9D

Q37838346-60B24DD6-65BE-4226-9CE1-B0BA38FB3386

Q37838346-61024702-2A79-48E6-931E-435BAF155D84

P304

Q37838346-09527A4F-37B6-4391-BDA7-33C4833BA21A

P31

Q37838346-2EAA23BD-5ED6-44F9-A71A-10C814C6FC03

P356

Q37838346-189CEB8E-A4CC-42B1-9CFA-88D4B063F8D6

P433

Q37838346-4B78319D-CCF6-43DA-96DF-F6B65E8A8F14

P478

Q37838346-FE0D520F-809A-4823-B835-A124039E87CB

P50

Q37838346-14549B5B-AF70-407C-8E15-2E33F09D571D

Q37838346-48C69D9B-C428-41A1-B49F-F386F91A683C

P577

Q37838346-4E5902F0-210D-4137-907F-B6002C12F44F

P5875

Q37838346-04F99838-4B3C-4023-9D06-467AA806BCE4

P698

Q37838346-54353363-614C-4120-AB9C-2284E13A6390

P356

P1433

Arthritis & Rheumatology

P1476

Does cancer that occurs during ...... treated with biologic agents.

@en

P2093

Anti-Rheumatic Therapy in Sweden Study Group

http://www.w3.org/2001/XMLSchema#string

Johan Askling

http://www.w3.org/2001/XMLSchema#string

Pauline Raaschou

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.

Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy.

Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials.

Ten years with biologics: to whom do data on effectiveness and safety apply?

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

P304

1812-1822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.30247

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49821412

http://www.w3.org/2001/XMLSchema#string

P698

21305513

http://www.w3.org/2001/XMLSchema#string